Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, No.201, Shipai Rd. Sec. 2, Beitou Dist., Taipei City, 112, Taiwan.
Department of Teaching and Research, Taipei City Hospital, Taipei City, 104, Taiwan.
Sci Rep. 2023 Mar 23;13(1):4773. doi: 10.1038/s41598-023-31346-9.
Circulating tumor cells (CTCs) in blood are accepted as a prognostic marker for patients with metastatic colorectal cancer (CRC). However, there is limited data on the use of CTCs as a prognostic marker for non-metastatic patients. In the current study, we used a rare cell automated analysis platform, the MiSelect R System, to enumerate CTCs from blood in non-metastatic CRC patients, and corelated the number of CTCs with the clinical staging and survival. The presence of CTCs in mesenteric vein blood (MVB) samples from 101 CRC patients was significantly associated with T stage. Patients with 1 or more CTCs per 8 mL of MVB exhibited significantly worse disease-free survival (DFS) and cancer-specific survival (CSS) compared to patient without CTCs. The presence of CTCs before surgery is an independent marker for both DFS and CSS. CTC presence after surgical resection is also a prognostic marker. CTCs are a potentially useful prognostic and predictive biomarker in non-metastatic CRC patients that may further stratify patient's risk status within different stages of disease.
循环肿瘤细胞（CTCs）在血液中被认为是转移性结直肠癌（CRC）患者的预后标志物。然而，关于 CTCs 作为非转移性患者的预后标志物的应用数据有限。在本研究中，我们使用罕见细胞自动分析平台 MiSelect R 系统从非转移性 CRC 患者的血液中计数 CTCs，并将 CTCs 数量与临床分期和生存相关联。101 例 CRC 患者肠系膜静脉血（MVB）样本中 CTCs 的存在与 T 分期显著相关。与无 CTCs 的患者相比，每 8ml MVB 中有 1 个或更多 CTCs 的患者无疾病进展生存期（DFS）和癌症特异性生存期（CSS）明显更差。手术前 CTCs 的存在是 DFS 和 CSS 的独立标志物。手术后 CTCs 的存在也是一个预后标志物。CTC 是一种潜在的有用的非转移性 CRC 患者的预后和预测生物标志物，可能进一步在疾病的不同阶段分层患者的风险状况。
